Vinit Karur, MD
Hematology & Oncology · Cortlandt Manor, NYNPI 1588825962
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (57.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Johnson & Johnson at 42.9% of the total. Reporting peaked in 2021 at $180 and has fallen 89.3% since, to $19 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 9 payments — averaging $46.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$180
- F. Hoffmann-la Roche AG$102
- Daiichi Sankyo Inc.$48
- AstraZeneca$45
- Bayer$30
- AVEO Pharmaceuticals, Inc.$15
Across 107 payments — averaging $5744.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$308K
- Genentech, Inc.$237K
- Acerta Pharma LLC$56K
- Bristol Myers Squibb$12K
- F. Hoffmann-la Roche AG$1K
- ADC Therapeutics America, Inc.$1K
What the payments were for
- Speaking & faculty fees$10224%
- Food & beverage$7819%
- Education$24057%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $180 |
| F. Hoffmann-la Roche AG | 1 | $102 |
| Daiichi Sankyo Inc. | 2 | $48 |
| AstraZeneca | 1 | $45 |
| Bayer | 2 | $30 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$420 in reported general payments places this provider in the 30th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 116 | $514,624 |
| Lenalidomide | 28 | $434,818 |
| ImbruvicaIbrutinib | 25 | $410,227 |
| NubeqaDarolutamide | 24 | $297,703 |
| PomalystPomalidomide | 12 | $276,637 |
| ErleadaApalutamide | 11 | $143,436 |
| LynparzaOlaparib | 11 | $124,356 |
| XtandiEnzalutamide | 12 | $88,519 |
| CreonLipase/Protease/Amylase | 17 | $73,077 |
| CresembaIsavuconazonium Sulfate | 12 | $72,965 |
| InqoviDecitabine/Cedazuridine | 12 | $63,630 |
| EliquisApixaban | 66 | $62,379 |
| XareltoRivaroxaban | 25 | $31,529 |
| Imatinib Mesylate | 19 | $19,584 |
| SavaysaEdoxaban Tosylate | 14 | $10,546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $30 | $297,70324 claims |
| Johnson & JohnsonErleada, Xarelto | $180 | $174,96536 claims |
| AstraZenecaLynparza | $45 | $124,35611 claims |
| Daiichi Sankyo Inc.Savaysa | $48 | $10,54614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Cortlandt Manor
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.